'Relief to poor': MNC patent on costly TB drug rejected, to 'help' generic production

By A Representative
On March 23, 2023, the Indian Patent Office (IPO) rejected pharma company Janssen’s application for an extension of its patent on bedaquiline, a drug used in the treatment of tuberculosis patients. The verdict that came just a day ahead of World Tuberculosis Day was celebrated by health activists and tuberculosis survivors in India.
Janssen, owned by multinational Johnson and Johnson, applied for an extension of their original patent on bedaquiline on the basis of having discovered a new formulation. According to Indian law, in order to be granted a patent extension in such a situation, the manufacturer has to show that the new formulation leads to an enhanced therapeutic effect. Janssen repeatedly failed to prove that in the case of bedaquiline salt formulation.
If the patent on bedaquiline had been extended, public and family budgets would have remained burdened by unjustifiable high costs of the drug. Bedaquiline is an important drug for TB patients on many counts. The older TB drugs include injectables such as kanamycin, which have severe side effects including permanent hearing loss. On the other hand, bedaquiline is an oral drug with much higher safety and efficacy profile.

Bedaquiline was the first new tuberculosis drug in forty years when it was approved by the US Food and Drug Administration in 2012. According to the most recent Global Tuberculosis Report, in 2021, India recorded 119,000 cases of multidrug resistant tuberculosis and over half a million deaths caused by the disease.
Priyam Lizmary Cherian, an intellectual property lawyer who argued the case at the IPO, said that the decision should ease the generic production of bedaquiline, making safe and effective treatment more accessible. “India, being a generic production hub, can count on companies being able to pick up production after the original patent expires in July 2023,” she said.
Widely recognized as a disease of the poor, tuberculosis is generally not a prominent field in Big Pharma research and development, although it affects the lives of hundreds of thousands in the Global South. In 2021, the money invested in this field globally was not even half of what a UN High Level Meeting identified as a target.
---
Source: Peoples Dispatch / Globetrotter News Service

Swami Vivekananda's views on caste and sexuality were 'painfully' regressive

By Bhaskar Sur* Swami Vivekananda now belongs more to the modern Hindu mythology than reality. It makes a daunting job to discover the real human being who knew unemployment, humiliation of losing a teaching job for 'incompetence', longed in vain for the bliss of a happy conjugal life only to suffer the consequent frustration.

Hoping against despair after Myanmar President’s visit to India

By Nava Thakuria Myanmar President U Min Aung Hlaing’s five-day official visit to India from 30 May to 3 June 2026 drew attention both in New Delhi and in India’s northeastern region, where policymakers and residents closely follow developments in the neighbouring country. The visit was significant because it touched on several issues of mutual concern, including security cooperation, border management, connectivity projects, trade, and regional stability.

Beyond data: The economist who refused to remain in the ivory tower

By Vikas Meshram There are few people who are born into privilege yet choose to dedicate their lives to the cause of the poor. Jean Drèze is one such individual. Born on January 22, 1959, in Leuven, Belgium, into the family of a distinguished economist, Drèze has become one of the most influential voices in the study of poverty, inequality, and social policy in India. Having lived in India since 1979, he adopted Indian citizenship in 2002 and has since played a pivotal role in shaping some of the country's most important welfare initiatives.

Counterview

Search This Blog